{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:54:48Z","timestamp":1787025288194,"version":"build-2736575974"},"reference-count":14,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Introduction<\/jats:bold>\n                    : Polycystic ovary syndrome (PCOS) is associated with increased cardiovascular risk later in life. Insulin resistance, common in PCOS, heightens the risk of type 2 diabetes, dyslipidemia, hypertension, and cardiovascular disease. This study explored whether insulin sensitizers could modify traditional cardiovascular risk factors, through influence on insulin resistance.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objectives<\/jats:bold>\n                    : To evaluate the impact of Metformin and Myoinositol therapy on glycemic and lipid profiles in PCOS patients, based on body mass index (BMI).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods<\/jats:bold>\n                    : A prospective, randomized clinical study was conducted at the UC for Endocrinology in Skopje (2022\u20132023). Women aged 18\u201340 with PCOS (Rotterdam 2003 criteria) were assigned to either Metformin (1500 mg XR) or Myoinositol (2 g + 200 mg folic acid TID) for 6 months. Parameters monitored included BMI, fasting plasma glucose (FPG), HOMA-IR, total cholesterol, LDL-C, HDL-C, triglycerides, lipid accumulation product (LAP), and TG\/HDL ratio.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                    : Baseline BMI significantly influenced HDL, triglycerides, TG\/HDL, and LAP. Myoinositol significantly improved cholesterol regardless of BMI. Among patients with BMI \u226525 kg\/m\u00b2, Metformin significantly reduced FPG (4.65 \u00b1 0.5 vs 5.01 \u00b1 0.3 mmol\/L) and HOMA-IR (2.25 \u00b1 0.6 vs 2.94 \u00b1 1.1 mmol\/L). HOMA-IR positively correlated with TG\/HDL ratio (R=0.2086, p=0.016).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion<\/jats:bold>\n                    : Myoinositol improved cholesterol in PCOS patients regardless of BMI. Metformin significantly affected glycemic control in overweight patients. The TG\/HDL ratio may serve as a predictive marker for insulin resistance in PCOS.\n                  <\/jats:p>","DOI":"10.2478\/prilozi-2025-0022","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T13:41:42Z","timestamp":1765287702000},"page":"51-62","source":"Crossref","is-referenced-by-count":1,"title":["Effect of Insulin Sensitizers on Glycemic and Lipid Profile in Patients with Polycystic Ovary Syndrome (PCOS)"],"prefix":"10.2478","volume":"46","author":[{"given":"Aleksandra","family":"Stevchevska","sequence":"first","affiliation":[{"name":"University Clinic for endocrinology, diabetes and metabolic disease , Clinical Center \u201cMother Theresa\u201d , Skopje , RN. Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Milenkovic","sequence":"additional","affiliation":[{"name":"University Clinic for endocrinology, diabetes and metabolic disease , Clinical Center \u201cMother Theresa\u201d , Skopje , RN. Macedonia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,12,6]]},"reference":[{"key":"2026071215563888393_j_prilozi-2025-0022_ref_001","doi-asserted-by":"crossref","unstructured":"Pililis, S.; Lampsas, S.; Kountouri, A.; Pliouta, L.; Korakas, E.; Livadas, S.; Thymis, J.; Peppa, M.; Kalantaridou, S.; Oikonomou, E.; et al. The Cardiometabolic Risk in Women with Polycystic Ovarian Syndrome (PCOS): From Patho-physiology to Diagnosis and Treatment. Medicina 2024, 60, 1656. https:\/\/doi.org\/10.3390\/medicina60101656","DOI":"10.3390\/medicina60101656"},{"key":"2026071215563888393_j_prilozi-2025-0022_ref_002","doi-asserted-by":"crossref","unstructured":"Kim JJ. Obesity and Polycystic Ovary Syndrome. J Obes Metab Syndr. 2024 Dec 30; 33(4): 289\u2013301. doi: 10.7570\/jomes24035. Epub 2024 Dec 20. PMID: 39701598; PMCID: PMC11704221.","DOI":"10.7570\/jomes24035"},{"key":"2026071215563888393_j_prilozi-2025-0022_ref_003","doi-asserted-by":"crossref","unstructured":"Bril F, Ezeh U, Amiri M, Hatoum S, Pace L, Chen YH, Bertrand F, Gower B, Azziz R. Adipose Tissue Dysfunction in Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023 Dec 21; 109(1): 10\u201324. doi: 10.1210\/clinem\/dgad356. PMID: 37329216; PMCID: PMC10735305.","DOI":"10.1210\/clinem\/dgad356"},{"key":"2026071215563888393_j_prilozi-2025-0022_ref_004","doi-asserted-by":"crossref","unstructured":"Bajuk Studen K, Pfeifer M. Cardiometabolic risk in polycystic ovary syndrome. Endocr Connect. 2018 Jul; 7(7): R238-R251. doi: 10.1530\/EC-18-0129. Epub 2018 May 29. PMID: 29844207; PMCID: PMC6026886.","DOI":"10.1530\/EC-18-0129"},{"key":"2026071215563888393_j_prilozi-2025-0022_ref_005","doi-asserted-by":"crossref","unstructured":"Amisi CA. Markers of insulin resistance in Polycystic ovary syndrome women: An update. World J Diabetes. 2022 Mar 15; 13(3): 129\u2013149. doi: 10.4239\/wjd.v13.i3.129. PMID: 35432749; PMCID: PMC8984569.","DOI":"10.4239\/wjd.v13.i3.129"},{"key":"2026071215563888393_j_prilozi-2025-0022_ref_006","doi-asserted-by":"crossref","unstructured":"Kim JJ, Choi YM. Dyslipidemia in women with polycystic ovary syndrome. Obstet Gynecol Sci. 2013 May; 56(3): 137\u201342. doi: 10.5468\/ogs.2013.56.3.137. Epub 2013 May 16. PMID: 24327994; PMCID: PMC3784112.","DOI":"10.5468\/ogs.2013.56.3.137"},{"key":"2026071215563888393_j_prilozi-2025-0022_ref_007","doi-asserted-by":"crossref","unstructured":"Milla AMG, Chagas EBF, Miola VFB, Zanuso B, de O, Guiguer EL, Ara\u00fajo AC, et al. Accuracy of visceral adiposity indices and lipid accumulation products in the identification of adults at high cardiovascular risk. Cl\u00ednica E Investig En Arterioscler. 2023. https:\/\/doi.org\/10.1016\/j.arteri.2023.04.002","DOI":"10.1016\/j.arteri.2023.04.002"},{"key":"2026071215563888393_j_prilozi-2025-0022_ref_008","doi-asserted-by":"crossref","unstructured":"Wild, Robert A. et al. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis; Fertility and Sterility, Volume 95, Issue 3, 1073\u20131079","DOI":"10.1016\/j.fertnstert.2010.12.027"},{"key":"2026071215563888393_j_prilozi-2025-0022_ref_009","unstructured":"Tsouma I, Kouskouni E, Demeridou S, Boutsikou M, et al. Lipid lipoprotein profile alterations in Greek infertile women with polycystic ovaries: influence of adipocytokines levels. In Vivo. 2014 Sep-Oct; 28(5): 935\u20139."},{"key":"2026071215563888393_j_prilozi-2025-0022_ref_010","unstructured":"Mirdamadi A, Riahinejad S, Varnaseri S. The association between anthropometric parameters and cardiovascular risk indicators in women with polycystic ovarian syndrome. ARYA Atheroscler. 2020 Jan; 16(1): 39\u201343. doi: 10.22122\/arya.v16i1.1804"},{"key":"2026071215563888393_j_prilozi-2025-0022_ref_011","doi-asserted-by":"crossref","unstructured":"Roa Barrios M, Arata-Bellabarba G, Valeri L, Vel\u00e1zquez-Maldonado E. Relationship between the triglyceride\/high-density lipoprotein-cholesterol ratio, insulin resistance index and cardiometabolic risk factors in women with polycystic ovary syndrome. Endocrinol Nutr. 2009 Feb; 56(2): 59\u201365. Spanish. doi: 10.1016\/S1575-0922(09)70553-4. Epub 2009 May 1. PMID: 19627713.","DOI":"10.1016\/S1575-0922(09)70553-4"},{"key":"2026071215563888393_j_prilozi-2025-0022_ref_012","doi-asserted-by":"crossref","unstructured":"Song do K, Lee H, Sung YA, Oh JY. Triglycerides to High-Density Lipoprotein Cholesterol Ratio Can Predict Impaired Glucose Tolerance in Young Women with Polycystic Ovary Syndrome. Yonsei Med J. 2016 Nov; 57(6): 1404\u201311. doi: 10.3349\/ymj.2016.57.6.1404. PMID: 27593868; PMCID: PMC5011272.","DOI":"10.3349\/ymj.2016.57.6.1404"},{"key":"2026071215563888393_j_prilozi-2025-0022_ref_013","doi-asserted-by":"crossref","unstructured":"Soldat-Stankovic V, Popovic Pejicic S, Stan-kovic S, Jovanic J, Bjekic-Macut J, Livadas S, Ognjanovic S, Mastorakos G, Micic D, Macut D. THE EFFECT OF MYOINOSITOL AND METFORMIN ON CARDIOVASCULAR RISK FACTORS IN WOMEN WITH POLYCYSTIC OVARY SYNDROME: A RANDOMIZED CONTROLLED TRIAL. Acta Endocrinol (Buchar). 2021 Apr-Jun; 17(2): 241\u2013247. doi: 10.4183\/aeb.2021.241. PMID: 34925574; PMCID: PMC8665246.","DOI":"10.4183\/aeb.2021.241"},{"key":"2026071215563888393_j_prilozi-2025-0022_ref_014","doi-asserted-by":"crossref","unstructured":"Kazerooni T, Shojaei-Baghini A, Dehbashi S, Asadi N, Ghaffarpasand F, Kazerooni Y. Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study. Fertil Steril. 2010 Nov; 94(6): 2208\u201313. doi: 10.1016\/j.fertnstert.2009.11.045. Epub 2010 Jan 15. PMID: 20079899.","DOI":"10.1016\/j.fertnstert.2009.11.045"}],"container-title":["PRILOZI"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/prilozi-2025-0022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:15:43Z","timestamp":1783901743000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/prilozi-2025-0022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":14,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,12,6]]},"published-print":{"date-parts":[[2025,11,1]]}},"alternative-id":["10.2478\/prilozi-2025-0022"],"URL":"https:\/\/doi.org\/10.2478\/prilozi-2025-0022","relation":{},"ISSN":["1857-8985"],"issn-type":[{"value":"1857-8985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,1]]}}}